PTGX250117P70000
- 0.00
- 0.000.00%
Protagonist Therapeutics Newsroom
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Clear Street Launches Healthcare & Biotechnology Equity Research
BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Protagonist Therapeutics Initiated at Outperform by BMO Capital
Protagonist Therapeutics Analyst Ratings
Goldman Sachs Initiates Protagonist Therapeutics(PTGX.US) With Hold Rating, Announces Target Price $47
BMO Capital Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $62
Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $58
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing
Protagonist Therapeutics(PTGX.US) Officer Sells US$5.64 Million in Common Stock
$Protagonist Therapeutics(PTGX.US)$ Officer Gupta Suneel sold 122.63K shares of common stock on Nov 25, 26, 2024 at an average price of $45.96 for a total value of $5.64 million.Source: Announcement
Protagonist Therapeutics(PTGX.US) Officer Sells US$4.68 Million in Common Stock
$Protagonist Therapeutics(PTGX.US)$ Officer PATEL DINESH V PH D sold 100K shares of common stock on Nov 25, 26, 2024 at an average price of $46.81 for a total value of $4.68 million.Source: